← Back to front page
United States · General news · New York Post

New Chinese weight-loss drug produces bigger results than Wegovy in under a year

Published by New York Post · United States 17 min ago
A Chinese-made drug could help people slim down even faster than other GLP-1s already on the market. colnihko – stock.adobe.com
A Chinese-made drug could help people slim down even faster than other GLP-1s already on the market. colnihko – stock.adobe.com · New York Post

Detailed summary

The race for the tiniest waist just got even more competitive.

New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year.

The findings suggest the newcomer could one day outperform some of the biggest names in the booming GLP-1 market, including Wegovy and Mounjaro.

In the 48-week trial, researchers from Fudan University in Shanghai recruited 567 adults who were overweight or obese and divided them into four groups.

Three groups received weekly injections of ribupatide at doses of 2 milligrams, 4 milligrams or 6 milligrams, while the fourth received a placebo.

Behind the experimental drug is Chinese pharmaceutical giant Hengrui, which partnered with US biotech firm Kailera Therapeutics to bring ribupatide to markets outside China.

Ribupatide works by mimicking two hormones naturally produced in the gut that help regulate appetite, digestion and blood sugar.

It’s a similar approach to that used by Eli Lilly’s blockbuster drugs Mounjaro and Zepbound. But ribupatide has been designed to bind more tightly to its targets and stay active in the body longer, potentially extending its effects throughout the week.

Everyone in the study — including those given placebo shots — also followed a lifestyle program that included dietary counseling and recommendations to get at least 150 minutes of moderate exercise each week.

After 48 weeks, those taking the lowest dose of ribupatide had lost an average of 10.7% of their starting body weight. Those on the 4-milligram dose shed 16.4%, while participants taking the highest dose lost a whopping 17.7%.

Opening of the article, excerpted from New York Post. To read the rest, open the article on the publisher's site.

Read the full article on New York Post Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (nypost.com)

Also worth reading